IL8sr-transduced PRAME-specific TAA-T cells

IL8sr-transduced PRAME-specific TAA-T cells are an investigational, genetically engineered tumor-associated antigen-specific T cell (TAA-T) therapy in which PRAME-directed T cells are further modified to express an interleukin-8 receptor (IL8sr) in order to enhance trafficking to PRAME-expressing tumors. PRAME (Preferentially Expressed Antigen in Melanoma) is a cancer-testis antigen overexpressed across multiple malignancies, including melanoma, leukemia, sarcoma, renal cell carcinoma, and Wilms tumor, with limited expression in normal tissues, making it a suitable target for adoptive T cell immunotherapy.[2][1] In this construct, PRAME-specific TAA-T cells—typically derived from donor or patient T cells and expanded ex vivo—are redirected to recognize PRAME-derived peptides presented on MHC molecules and endowed with IL8 receptor signaling to improve homing to IL-8–rich tumor microenvironments, with the aim of increasing antitumor cytotoxicity against PRAME-positive, high-risk or relapsed/refractory solid tumors and possibly hematologic malignancies.[2][1]